Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 376 to 400 of 410

Guidance and quality standards awaiting development
Title	Type
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]	Technology appraisal guidance
Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]	Technology appraisal guidance
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]	Technology appraisal guidance
Troriluzole for spinocerebellar ataxia [ID6456]	Technology appraisal guidance
Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]	Technology appraisal guidance
Tucatinib with trastuzumab and oxaliplatin-based chemotherapy for untreated HER2-positive metastatic or unresectable colorectal cancer [ID6755]	Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]	Technology appraisal guidance
Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666]	Technology appraisal guidance
Upadacitinib for treating moderately to severely active systemic lupus erythematosus [TSID12366]	Technology appraisal guidance
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]	Technology appraisal guidance
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]	Technology appraisal guidance
Veligrotug for treating thyroid eye disease [ID6636]	Technology appraisal guidance
Venglustat for treating Fabry disease	Technology appraisal guidance
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]	Technology appraisal guidance
VER-01 for treating chronic low back pain [ID6638]	Technology appraisal guidance
Vertebral body tethering for idiopathic scoliosis in children and young people	HealthTech guidance
Vilobelimab for treating COVID 19 [TSID11815]	Technology appraisal guidance
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]	Technology appraisal guidance
Vonaprument for treating geographic atrophy caused by age-related macular degeneration	Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]	Technology appraisal guidance
Vulnerable populations: strategies for tackling inequalities	Quality standard
VX-522 for treating cystic fibrosis unresponsive to CFTR modulators when there are 2 mutations in the CFTR gene [TSID12431]	Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]	Technology appraisal guidance
Xanomeline tartrate–trospium chloride for treating psychosis associated with Alzheimer's disease	Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]	Technology appraisal guidance

Results per page

10
25
50
All